EDTA for Injection Recalled Due to Sterility Assurance Defect
GenoGenix LLC is recalling all lots of EDTA for Injection nationwide due to lack of assurance of sterility, affecting all strengths and presentations.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II recall for a sterility assurance issue in injectable medication. No illnesses or injuries have been reported in the source material. This qualifies as a risk-of-harm product where injury has not yet been reported, meeting the rubric criterion for score 3 (High).
Plain-English summary
GenoGenix LLC is recalling all lots and presentations of EDTA for Injection nationwide due to lack of assurance of sterility. The recall encompasses all product that remains within its expiration date.
Sterility is critical for injectable medications. The manufacturer has determined that assurance of sterility cannot be provided for the affected lots. This recall applies to all strengths and presentations of EDTA for Injection.
Patients and healthcare providers who have EDTA for Injection from this recall should not use the product. Individuals currently taking this medication should consult with their healthcare provider about alternative options.
The recalled product
- Product
- EDTA for Injection, all strengths and presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692.
- Manufacturer
- GenoGenix LLC
- Category
- Drug — Injectable Pharmaceutical
- Hazard
- lack-of-sterility
- contamination-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All lots within expiry.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27